Millendo Therapeutics with ticker code (MLND) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 5 and 2 with a mean TP of 4. Now with the previous closing price of 2.25 this would indicate that there is a potential upside of 77.8%. The 50 day MA is 1.79 and the 200 day MA is 1.79. The market capitalisation for the company is $43m. Company Website: http://www.millendo.com
The potential market cap would be $76m based on the market concensus.
Millendo Therapeutics, a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
